Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03033056 · ClinicalTrials.gov registry record
Neurobiology of Generalized Fear-Conditioning & Avoidance in Anxiety Disorders
A clinical trial, sponsored by University of Minnesota.
- Completed
- Registry status
- 208
- Enrollment target
NCT03033056: Completed study, sponsored by University of Minnesota.
NCT03033056 is a clinical trial that has completed, run by University of Minnesota. The registered enrollment target is 208 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03033056 has completed, sponsored by University of Minnesota.
- COMPLETED
- Registry status
- 208 participants
- Enrollment target
Study Summary
Anxiety disorders are among the most prevalent, costly, and disabling mental illnesses. One central, yet largely understudied, abnormality in anxiety disorders is the heightened tendency to display fear and avoidance in reaction to benign or safe events that resemble feared situations. The current project maps brain circuits associated with this abnormality in order to contribute to future brain-based diagnosis and treatments for clinical anxiety.
Primary Outcome
Blood oxygenation level dependent responses elicited during the fear conditioning paradigm
Interventions
- BEHAVIORAL Test of fear conditioning
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 208 participants |
| Start Date | 2017-07-17 |
| Est. Completion | 2021-08-01 |
What the finished NCT03033056 record still lists
NCT03033056 is an observational study that tracks outcomes without assigning an intervention. The registered 208 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 1 intervention - of which Test of fear conditioning is the first listed.
NCT03033056 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03033056 about?
NCT03033056 is a clinical study titled "Neurobiology of Generalized Fear-Conditioning & Avoidance in Anxiety Disorders". Anxiety disorders are among the most prevalent, costly, and disabling mental illnesses. One central, yet largely understudied, abnormality in anxiety disorders is the heightened tendency to display fear and avoidance in reaction to benign or safe events that resemble feared situations. The current p...
What is the current status of trial NCT03033056?
This trial is currently completed. The enrollment target is 208 participants. The study started on 2017-07-17. Estimated completion is 2021-08-01.
What interventions are being tested in trial NCT03033056?
The interventions under investigation include: Test of fear conditioning (BEHAVIORAL).
Who is sponsoring clinical trial NCT03033056?
This trial is sponsored by University of Minnesota, which has 966 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03465774 · 208 participants
Indwelling Pleural Catheters With or Without Doxycycline in Treating Patients With Malignant Pleural Effusions
- NCT03803332 · 208 participants · NA
A Trial Comparing Interpersonal Therapy to Exposure Therapy for PTSD Due to Military Sexual Trauma (MST) in Male and Female Military Personnel
- NCT04732065 · 208 participants · Phase 1
ONC206 for Treatment of Newly Diagnosed, Recurrent Diffuse Midline Gliomas, and Other Recurrent Malignant CNS Tumors
- NCT05293756 · 208 participants · NA
OPtimizing Technology to Improve Medication Adherence and BP Control (OPTIMA-BP)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI